**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Expert Review ALL | **Project Code** | **PI4VVR082** |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Janice Galleshaw |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**October 2014**

**Project Type**

Expert Review (Video)

Downloadable Slides

Podcast

Other:

**Email Blast Included?**

Yes

No

**Subject Line:** New Expert Review on ALL: Asparaginase Therapy and the Role for Therapeutic Drug Monitoring

**Number of E-Blasts**

Only One

Two  
Other Amount:

Speciality lists: ASBMT, ASPHO

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)

Additional Emails (Supporters?):

Rachel.Every@jazzpharma.com

([Francois.DiTrapani@jazzpharma.com](mailto:Francois.DiTrapani@jazzpharma.com))

jessica.mendoza@jazzpharma.com

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**2014 Exp Review ALL**

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**In terms of LEAN, virtual products differ in that all sections should be complete prior to sending this form to Web (there is no minimum number of sections).**

1. **[Title---always italicized, no bold, no quotes]**

*Expert Review on Acute Lymphoblastic Leukemia: Asparaginase Therapy and the Role for Therapeutic Drug Monitoring*

1. **[Activity Date]**

**Release Date:**

November XX, 2014

**Expiration Date:**

November XX, 2015

1. **[Activity Overview]**

This CME-certified Expert Review features discussions on the management of patients with acute lymphoblastic leukemia (ALL), focusing on asparaginase therapy and the role for therapeutic drug monitoring.

1. **[Target Audience]**

This educational activity is designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with acute lymphoblastic leukemia (ALL).

1. **[Learning Objectives]**

After successful completion of this educational activity, participants should be able to:

* Identify best practices for implementing therapeutic drug monitoring and managing hypersensitivity to optimize the use of asparaginase therapy in patients with acute lymphoblastic leukemia (ALL)
* Employ recent advances regarding the utilization of asparaginase therapy in patients with ALL based on emerging clinical trial data and current treatment recommendations

***[NOTE: learning objectives must be specific, measurable, attainable, relevant, time limited]***

1. **[Faculty Listing/Featured Experts/Discussants….Faculty Listing and Featured Experts sections are stacked, Discussants section is in-line]**

**Discussants**

**Stephen Hunger, MD**

University of Colorado Denver

Denver, Colorado, United States

**Rob Pieters, MD, PhD**

Princess Máxima Center for Pediatric Oncology

Utrecht, the Netherlands

1. **[Featured Abstracts/Discussion Topics/Activity Topics] –note to Web, please make the green highlighted text a live link to the URLs listed immediately afterward**

*Erwinia* asparaginase achieves therapeutic activity after pegaspargase allergy: A report from the Children’s Oncology Group

Salzer W, et al. *Blood.* 2013;122(4):507-514. [[http://www.bloodjournal.org/content/122/4/507.long?sso-checked=true]]

Postinduction dexamethasone and individualized dosing of *Escherichia coli* L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Vrooman LM, et al. *J Clin Oncol*.2013;31(9):1202-1210. [[http://jco.ascopubs.org/content/31/9/1202.long]]

A prospective study on drug monitoring of PEGasparaginase and *Erwinia* asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Tong WH, et al. *Blood.* 2014;123(13):2023-2033. [[http://www.bloodjournal.org/content/123/13/2026.long?sso-checked=true]]

1. **Provider**

This activity is provided by prIME Oncology.

1. **[Continuing Education---choose one]**

**US CME**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this enduring activity for a maximum of *XX AMA PRA Category 1 Credit(s)™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

\*\*All CME/CE verbiage should receive final approval from Regulatory/Compliance Manager

**Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx) [[link to our Terms page]]

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 80% or higher.

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by grant from Jazz Pharmaceuticals.

1. **[Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Hunger has disclosed that he has received consulting fees from Jazz Pharmaceuticals and Sigma Tau Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pieters has disclosed that he has received consulting fees from Jazz Pharmaceuticals, EUSA Pharma, Medac Pharma, and Sigma Tau Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical content reviewer/planner) - no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) - no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[URL and Mobile App Name---give suggestions for URL name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

Insert URL here.

www.primeoncology.org/2014expertreviewALL

\*\*Note: Do not include the name of the congress or society in the URL.

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **Exp Review ALL**

Meta Description

In this educational activity, expert faculty will provide a concise yet comprehensive discussion on the management of patients with ALL, focusing on asparaginase therapy and the role for therapeutic drug monitoring

Key Words/Key Phrases

ALL

Acute lymphoblastic leukemia

Asparaginase

pediatric acute lymphoblastic leukemia

Therapeutic drug monitoring

Hypersensitivity

Erwinia asparaginase

***Escherichia Coli* L-asparaginase**

**ALL Consortium Protocol 00-01**

**PEGasparaginase**

**asparaginase antibodies**

**pegaspargase allergy**

**Stephen Hunger**

**Rob Pieters**

1. **[Subject Line for Email Blast]**

A. Insert Email Blast Subject Line A copy here.

1. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (with no logos)

Fee Statement

**15. [Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

Listing: 2014 Expert Review on Acute Lymphoblastic Leukemia: Asparaginase Therapy and the Role for Therapeutic Drug Monitoring

Description: Stephen Hunger, MD, from University of Colorado Denver, Denver, Colorado, United States, and Rob Pieters, MD, PhD, from Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, discuss management of patients with ALL, focusing on asparaginase therapy and the role for therapeutic drug monitoring